Supporting next‑generation infectious disease programs

We fast‑track infectious disease programs with specialized assays, GxP & CLIA processes, and scientific expertise to generate reliable, decision‑ready data.

infectious-disease-what-we-do

What we do

  • End‑to‑end lab support for trials from pre-clinical through post-marketing surveillance

  • Fit‑for‑purpose and fully validated assays for virology, bacteriology, mycology, and parasitology

  • Rapid onboarding of novel and exploratory biomarkers to match your mechanism and endpoints

  • Custom assay development, transfer and/or bridging 

  • Collaborative consultation on protocol design, endpoints, and biomarker strategy

Pathogen coverage

  • Viral: respiratory (e.g., influenza, RSV), herpesviruses, hepatitis, HIV, emerging and re‑emerging viruses

  • Bacterial: antimicrobial resistance panels, respiratory and bloodstream pathogens, atypicals

  • Fungal: invasive candidiasis, aspergillosis, endemic mycoses, molds and yeasts

  • Parasitic: protozoa and helminths

  • Vaccine studies: immunogenicity, correlates of protection (CoP), durability of response

infographic-of-hpv-cells-infection-with-human-tissue-microscopic-view-high-contrast-colors-to-emphasize-the-battle
elisa

Specialty assay platforms

  • Molecular: qPCR/ddPCR, multiplex PCR panels, NGS for typing, resistance, and surveillance

  • Serology & immunology: ELISA, multiplex cytokine/chemokine, neutralization assays (virus or pseudovirus), flow cytometry (phenotyping, activation, ICS and proliferation)

  • Culture‑based & phenotypic: pathogen isolation, MIC determination, susceptibility testing

  • Biomarkers: inflammatory, endothelial, and host‑response panel

  • Cell‑based functional: ADCC/CDC, T‑cell activation, cytokine release, and mechanistic readouts